NASDAQ : KYTX
Kyverna Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 5.67 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 350.65M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 350.65M |
| Enterprise Value | 184.22M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 61.84M |
| Shares Outstanding | 61.84M |
| Shares Change (YoY) | +22.58% |
| Shares Change (QoQ) | +0.77% |
| Owned by Insiders (%) | 1.79% |
| Owned by Institutions (%) | 44.53% |
| Float | 36.06M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 138.76 |
| PB Ratio | 2.11 |
| P/TBV Ratio | 2.12 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 9.06 |
| Quick Ratio | 8.75 |
| Debt / Equity | 0.20 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -88.69 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -87.24% |
| Return on Assets (ROA) | -44.51% |
| Return on Invested Capital (ROIC) | -51.09% |
| Return on Capital Employed (ROCE) | -80.67% |
| Weighted Average Cost of Capital (WACC) | 14.63% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.02M |
| Employee Count | 149 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 2.07 |
| 52-Week Price Change | -20.92% |
| 50-Day Moving Average | 6.91 |
| 200-Day Moving Average | 8.09 |
| Relative Strength Index (RSI) | 40.83 |
| Average Volume (20 Days) | 841,740 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 9.54M |
| Short Previous Month | 9.62M |
| Short % of Shares Out | 15.43% |
| Short % of Float | 26.46% |
| Short Ratio (days to cover) | 9.45 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -158.93M |
| Pretax Income | -152.64M |
| Net Income | -152.64M |
| EBITDA | -157.36M |
| EBIT | -158.93M |
| Earnings Per Share (EPS) | -$2.88 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 199.43M |
| Total Debt | 33.00M |
| Net Cash | 166.43M |
| Net Cash Per Share | $2.69 |
| Equity (Book Value) | 165.55M |
| Book Value Per Share | 2.69 |
| Working Capital | 183.74M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -158.75M |
| Capital Expenditures | -294,000 |
| Depreciation & Amortization | 1.57M |
| Net Borrowing | 24.31M |
| Free Cash Flow | -159.05M |
| FCF Per Share | -$2.57 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -22.58% |
| Shareholder Yield | -22.58% |
| Earnings Yield | -50.81% |
| FCF Yield | -45.36% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $30.40 |
| Price Target Difference | 436.16% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |